MedComm,
Journal Year:
2024,
Volume and Issue:
5(12)
Published: Dec. 1, 2024
Abstract
The
skin
serves
as
the
first
protective
barrier
for
nonspecific
immunity
and
encompasses
a
vast
network
of
skin‐associated
immune
cells.
Atopic
dermatitis
(AD)
is
prevalent
inflammatory
disease
that
affects
individuals
all
ages
races,
with
complex
pathogenesis
intricately
linked
to
genetic,
environmental
factors,
dysfunction
well
dysfunction.
Individuals
diagnosed
AD
frequently
exhibit
genetic
predispositions,
characterized
by
mutations
impact
structural
integrity
barrier.
This
leads
release
alarmins,
activating
type
2
pathway
recruiting
various
cells
skin,
where
they
coordinate
cutaneous
responses.
In
this
review,
we
summarize
experimental
models
provide
an
overview
its
therapeutic
interventions.
We
focus
on
elucidating
intricate
interplay
between
system
regulatory
mechanisms,
commonly
used
treatments
AD,
aiming
systematically
understand
cellular
molecular
crosstalk
in
AD‐affected
skin.
Our
overarching
objective
novel
insights
inform
potential
clinical
interventions
reduce
incidence
AD.
medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: June 19, 2024
ABSTRACT
Atopic
dermatitis
(AD)
is
a
highly
heritable
and
common
inflammatory
skin
condition
affecting
children
adults
worldwide.
Multi-ancestry
approaches
to
AD
genetic
association
studies
are
poised
boost
power
detect
signal
identify
ancestry-specific
loci
contributing
risk.
Here,
we
present
multi-ancestry
GWAS
meta-analysis
of
twelve
cohorts
from
five
ancestral
populations
totaling
56,146
cases
602,280
controls.
We
report
101
genomic
associated
with
AD,
including
15
that
have
not
been
previously
or
eczema.
Fine-mapping,
QTL
colocalization,
cell-type
enrichment
analyses
identified
genes
cell
types
implicated
in
pathophysiology.
Functional
keratinocytes
provide
evidence
for
could
play
role
through
epidermal
barrier
function.
Our
study
provides
new
insights
into
the
etiology
by
harnessing
multiple
functional
unveil
mechanisms
which
AD-associated
variants
impact
types.
Disclosure
Statement
BRG,
MO,
CH,
KMS
employees
AbbVie.
FT
was
an
employee
AbbVie
at
time
study.
JEG
(University
Michigan)
has
received
research
support
AbbVie,
Janssen,
Almirall,
Prometheus
Biosciences/Merck,
BMS/Celgene,
Boehringer
Ingelheim,
Galderma,
Eli
Lilly,
advisor
Sanofi,
BMS,
Ingelheim.
MKS,
RU,
MTP,
QL,
RW,
JMK,
LCT
University
Michigan
no
funding
disclose.
MEM,
AHS,
FDM,
DW,
JTG,
HH
Children’s
Hospital
Philadelphia
The
design,
conduct,
financial
this
were
provided
participated
interpretation
data,
review,
approval
publication.
Allergy,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 27, 2024
Abstract
The
incidence
of
allergic
diseases
has
been
rising
over
the
past
decades,
and
this
troubling
trend
coincides
with
environmental
changes
such
as
shifts
in
diet
increased
antibiotic
use,
both
which
can
impact
our
immune
system.
Allergic
reactions
occur
when
system
overreacts
to
normally
harmless
substances,
it
is
known
that
regulatory
T
cells
(Tregs)
play
a
major
role
suppression
generation
tolerance.
However,
new
research
suggests
Tregs
malfunction
environments
promote
allergies.
This
review
delves
into
Treg
function,
how
factors
influence
their
ability
maintain
homeostasis.
Specifically,
we
explore
origins
cells,
well
mechanisms
used
for
inflammation
tissue
healing,
concentration
on
food
allergies,
atopic
dermatitis
asthma.
Understanding
function
context
changing
environment
crucial
developing
strategies
prevent
treat
Journal of Investigative Dermatology,
Journal Year:
2024,
Volume and Issue:
144(5), P. 917 - 918
Published: April 19, 2024
The
progress
in
our
understanding
of
atopic
dermatitis
(AD)
(atopic
eczema)
the
last
10
years
has
been
remarkable.
Nearly
half
scientific
papers
ever
published
on
AD
have
written
years.
This
contribution
knowledge,
parallel
with
technological
and
pharmaceutical
progress,
transformed
ability
to
treat
some
most
severe
forms
AD.
Notably,
we
seen
advent
biologics
such
as
anti–IL-4
receptor
biologic
dupilumab
(Simpson
et
al,
2016),
2
anti–IL-13
agents
(tralokinumab
[Wollenberg
2021]
lebrikizumab
[Silverberg
2023]),
small-molecular
Jak
inhibitors
(the
Jak1
upadacitinib
[Guttman-Yassky
abrocitinib
[Simpson
2020]
Jak1/Jak2
inhibitor
baricitinib
[Zhou
2021]).
Veterinary Dermatology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 25, 2024
Abstract
Atopic
dermatitis
(AD)
is
a
common
and
chronic
inflammatory
skin
disease
with
frequent
relapses.
The
genomics
revolution
has
greatly
contributed
revolutionised
our
knowledge
of
human
AD;
understanding
the
molecular
fingerprint
AD
associated
pathogenic
immune
pathways
led
to
preclinical
assessments
several
novel
treatments.
Initial
studies
using
microarray
analysis
analyse
transcriptome
(gene
expression)
changes
provided
relevant
insight
on
structural
occurring
at
time
acute
or
lesions,
after
immunomodulating
treatments
drugs
ciclosporin
dupilumab,
monoclonal
antibody
anti‐IL4
receptor.
revealed
that
characterised
by
activation
multiple
cytokine
(predominance
T
helper
cell
[Th]2
some
Th1,
Th17
Th22)
as
well
dysregulated
expression
barrier
components
in
skin.
There
are
reports
different
single
targets
(e.g.
interleukin
[IL]‐13,
CCL17
periostin)
spontaneous
canine
(cAD).
However,
significant
have
been
limited
study
analysing
lesions
dogs.
While
revealing
large
number
genes
differentially
expressed
cAD
skin,
small
sample
size
(n
=
13
dogs)
lack
key
epidermal
microarrays
inhibited
discussion
towards
specific
immunological
changes.
This
review
summarises
current
literature
regarding
mechanisms
cAD,
including
recent
data
RNA
sequencing,
compares
aspects
previously
published
from
AD.
